Iron Protein Succinylate Environmental Risk Assessment (ERA) report
Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
Not available
Drug class
Oral iron replacement complexferric iron–protein succinylate
Mechanism of action
A ferric iron–protein succinylate complex designed to maintain iron solubility in the gastrointestinal tract and deliver iron for absorption. The protein component is digested in the small intestine, releasing iron for transferrin transport and haemoglobin synthesis.
Indications / reported uses
Oral treatment of iron deficiency and iron-deficiency anaemia with formulations authorised for ferric protein succinylate; elemental iron content and dosage are product-specific.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Iron Protein Succinylate Environmental Risk Assessment (ERA) (the Iron Protein Succinylate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.